This article is more than 5 years old. Information may no longer be current.
Patent office issues notice of allowance to InSite for DuraSite 2
InSite Vision received a notice of allowance from the U.S. Patent and Trademark Office for its DuraSite 2 drug delivery system, according to a news release.
The patent should provide protection for the DuraSite 2 sustained delivery technology and drugs formulated with it through 2029, the release said.
DuraSite 2, as well as DuraSite, can be customized to deliver a variety of solutions, gels and suspensions via a synthetic polymer-based formulation that results in extended residence time compared with conventional topical therapies, according to the release.
A DuraSite 2 formulation demonstrated twice the concentration in the aqueous humor of a DuraSite formulation and four times the concentration of the drug alone in a large comparative study, the InSite release said.
DuraSite 2 may allow treatment of posterior segment diseases with topical drops instead of injections, according to the release.